本文已被：浏览 353次 下载 228次
投稿时间：2021-11-23 网络发布日期：2022-06-20
投稿时间：2021-11-23 网络发布日期：2022-06-20
中文摘要: IgA肾病被认为是全身免疫性疾病，其发病机制复杂，现有的治疗方法并不能完全控制IgA肾病的进展，约40%的患者会在20年后进入终末期肾功能衰竭。近年来，针对IgA肾病致病位点（特别是半乳糖缺陷IgA1的生成和免疫复合物引起的炎症反应）的靶向治疗正在积极开展。本文针对IgA肾病的发病机制，从黏膜免疫、B细胞、IgA1蛋白酶、补体途径、RNA等方面介绍目前IgA肾病的靶向治疗方法及其相关机制，以期对未来IgA肾病的特异性治疗提供新的思路和方向。
Abstract:IgA Nephropathy (IgAN) is considered as a systemic immune disease with complex pathogenesis, the existing treatment methods cannot completely control the progression of IgAN, and about 40% of the patients reach end-stage renal failure after 20 years. In recent years, targeted therapy for the pathogenic loci of IgAN (especially the production of galactose-deficient IgA1 and the inflammatory response caused by immune complexes) has been actively developed. In this paper, the current targeted therapy of IgAN and its related mechanisms were introduced in detail from aspects of IgA1 protease, mucosal immunity, B cells, complement pathway and RNAs, in order to provide new ideas and directions for the specific treatment of IgAN in the future.
keywords: IgA nephrology Immune Pathogenesis Targeted therapy Galactose deficiency B cells Inflammatory reaction
文章编号： 中图分类号：R692.6 R965 文献标志码：A
基金项目:山西省科学技术厅重点研发计划项目（201803D31163）；山西省卫计委科研项目（201713）；山西省研究生教育创新项目（2020SY279）；山西省“136”兴医工程领军临床专科科研项目（xy2018003）
| Author Name | Affiliation |
| FAN Qi-qiang， WANG Zong-yu， ZHOU Yun | Department of Neporology， the Fifth Clinical Medical College of Shanxi Medical University， Taiyuan 030012， China |
引用文本：
范琦强，王宗隅，周芸.IgA肾病的靶向治疗及其相关机制[J].中国临床研究,2022,35(6):861-865.
范琦强，王宗隅，周芸.IgA肾病的靶向治疗及其相关机制[J].中国临床研究,2022,35(6):861-865.